Bavarian Nordic Secures Major Funding for Smallpox and Monkeypox Vaccine Production

US Government Provides USD 1.568 Billion for Enhanced Vaccine Production

Contract Supports Inventory Replenishment for Freeze-Dried Vaccines

[City, Date] - Bavarian Nordic, a leading biotechnology company, has received a substantial order from the US government for its smallpox vaccine, Jynneos. The USD 1.568 billion contract will bolster inventory of bulk vaccine, enabling the production and supply of freeze-dried vaccines for future use.

This significant development comes in response to the recent commercial launch of JYNNEOS Smallpox and Monkeypox Vaccine Live Nonreplicating in the United States. The vaccine has demonstrated strong efficacy and safety in preventing both smallpox and monkeypox.

The replenishment of bulk vaccine inventory is crucial for maintaining a robust national stockpile and ensuring adequate supply in the event of an outbreak. The funding will also support continued research and development of Jynneos to further enhance its effectiveness and safety.

Conclusion

Bavarian Nordic's collaboration with the US government underscores the critical role of biotechnology in protecting public health. This investment in vaccine production not only safeguards the nation against smallpox and monkeypox but also lays the foundation for a more resilient healthcare system ready to respond to future pandemics.